Our Approach
At Enliven Therapeutics, our primary focus lies in opportunities emerging from validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs. By combining clinically validated targets and specific target product profiles with disciplined clinical trial design and regulatory strategy, we aim to develop drugs that address unmet needs with an increased probability of clinical and commercial success.
The Enliven Difference
We aim to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being for patients. A significant unmet need remains for the majority of patients for whom no targeted therapies exist or whose disease has developed resistance to currently available targeted treatments. For those on existing therapies, poor drug tolerability can both limit and diminish gains in survival. Additionally, efficacy-related challenges like drug resistance and disease recurrence have emerged, hindering patients’ quality of life and longevity.
We believe the success of next generation therapeutics depends not only on clinical efficacy, but also on a differentiated product profile, including tolerability, dosing regimen, and specific drug administration requirements, that drives widespread adoption by patients, physicians, and payors in the real world.
Using our expertise and the foundational principles driving our approach, we believe we are in a unique position to develop targeted therapies to help people not only live longer, but live better.
Best-In-Class & First-in-Class
Our primary focus lies in opportunities emerging from validated biology, where we believe we can improve upon the standard of care. Our science addresses the challenges of existing therapies–tolerability, combinability and emerging issues like resistance and disease progression–with a novel precision oncology approach.
Unique Insights Applied to Validated Biology
Utilizing our deep understanding of fundamental genetic drivers in diseases and insights from real-world market research, we can efficiently pursue novel approaches to target emerging and clinically validated oncogenic drivers and signaling nodes.
Not All Chemistry is Created Equal
We have a deep understanding of our chemical space. This enables us to rapidly synthesize advanced libraries of diverse drug-like compounds for our selected target opportunities in a highly efficient discovery process that is difficult for companies with larger pipelines and broader focus to match.
Disciplined Clinical and Regulatory Strategy
Our development efforts utilize biomarker-guided patient selection to build a high-quality dataset to test efficacy early and provide opportunities to enable future trials in earlier lines of therapy.